✓
Open
20 Feb 2026
✓
Close
24 Feb 2026
3
Allotment
—
✓
Listing
Fri, Feb 27, 2026
Price Band
₹75 to ₹79
Issue Size
2,08,86,200 shares (agg. up to ₹165 Cr)
Lot Size
189 Shares
Listing Date
Fri, Feb 27, 2026
Latest GMP
₹0
Est. Gain
0%
✦ AI Insight
GMP Trend
27-02-2026₹0Est. ₹79+0%
26-02-2026₹0Est. ₹79+0%
25-02-2026₹-4Est. ₹75-5.06%
Live Subscription
| Category | Subscription (times) |
|---|---|
| Total | 5.23x |
Restated Financials (₹ Cr.)
| Period Ended | 30 Sep 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 106.62 | 88.51 | 51.01 | 36.63 |
| Total Income | 49.75 | 70.96 | 48.15 | 44.26 |
| Profit After Tax | 12.51 | 19.13 | 10.32 | 13.53 |
| EBITDA | 18.95 | 28.63 | 19.27 | 20.07 |
| NET Worth | 58.85 | 46.30 | 26.99 | 22.73 |
| Reserves and Surplus | 28.16 | 15.60 | 26.00 | 21.74 |
| Total Borrowing | 22.51 | 18.93 | 15.73 | 9.78 |
| Amount in ₹ Crore |
Peer Comparison
| Company | Issue Type | Issue Size | Issue Price | PE Ratio | Listing Day Close | Listing Gain/Loss % | LTP |
|---|---|---|---|---|---|---|---|
| Nephrocare Health Services Ltd. | Mainboard | ₹871.05 Cr | ₹460 | 63.52 | ₹471.25 | +2.45% | ₹635.80 (+0.07%) |
| Modern Diagnostic & Research Centre Ltd. | SME | ₹36.89 Cr | ₹90 | 11.04 | ₹94.99 | +5.54% | ₹49.00 (-3.92%) |
| Invicta Diagnostic Ltd. | SME | ₹28.12 Cr | ₹85 | 14.51 | ₹96.70 | +13.76% | ₹68.50 (+0.74%) |
| Star Imaging & Path Lab Ltd. | SME | ₹69.47 Cr | ₹142 | 12.01 | ₹135.95 | -4.26% | ₹95.48 (-0.59%) |
Objects of the Issue
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Funding capital expenditure towards establishment of New IVF Centers of the Company. | 50.00 |
| 2 | Repayment/pre-payment, in full or in part, of certain outstanding loans availed by the Company. | 20.00 |
| 3 | General Corporate Purposes | 12.28 |
| 4 | Issue Expenses | 14.15 |
| Total | 96.43 |
About Gaudium IVF IPO
Incorporated in March 2015, Gaudium IVF and Women Health Limited have engaged in In Vitro Fertilization (IVF) treatments throughout India and have expanded into several states utilizing a hub-and-spoke model. The company operates over thirty locations, which include seven hubs (centres) and twenty-eight spokes. The organization has entered into a strategic alliance with Infertility Experts, known as Spokes, to achieve the mutual objective of raising awareness regarding Assisted Reproductive Technology (ART) and In Vitro Fertilization (IVF) treatments. The company serves patients from various countries, including Canada, the United Kingdom, the United States, Kenya, South Africa, and Oman. The company has centres in major cities: two in Delhi (Janakpuri, Kailash Colony), and one each in Mumbai (Khar West), Ludhiana, Srinagar, Patna, and Bangalore, covering key locations across India. The company offers specialized fertility services, including In Vitro Fertilization (IVF), Intracytoplasmic Sperm Injection (ICSI), Intrauterine Insemination (IUI), and ovulation induction. The company's treatments are designed for various infertility challenges for both genders. The company also provid
Contact Details
Gaudium IVF & Women Health Ltd. AddressB1/51, Janak PuriB-1New Delhi, New Delhi, 110058011-4885 8585compliance@gaudiumivfcentre.comVisit Website